AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 282 min read$BSX

Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating

Oppenheimer cut Boston Scientific's (BSX) price target to $65 from $85 due to a cybersecurity disruption and competitive pressures, but maintained an Outperform rating. The firm reduced fiscal 2026 and 2027 estimates, citing the impact of an eight-day cyberattack and competition in LAAC and EP markets. Boston Scientific reported $5.44 billion in Q2 revenue, up 7.5% YoY, but expects the cyberattack to materially impact Q3 and full-year 2026 results.

Original reporting
insidermonkey.com
Published Sep 28, 2026, 6:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 7:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$BSXBearishMed
01

Why it matters

The analyst's PT cut reflects both the immediate disruption and longer‑term competitive concerns, creating a bearish bias for the stock.

02

Market read

Analyst price‑target reduction is a fresh catalyst that can drive short‑term price movement ahead of upcoming earnings.

03

What to watch

Potential upside from the pulsed‑field ablation portfolio and recovery of back‑logged orders.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Boston Scientific reported a cyberattack that halted manufacturing for eight days and faces competitive softness in its LAAC and EP businesses.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Oppenheimer lowered Boston Scientific's price target to $65 from $85, citing cyberattack impact and competitive pressure in LAAC and EP.

Expected impact

likely pressure as the market prices in the lower target and revised estimates

Evidence & confidence

The PT cut is a fresh analyst action that directly affects valuation expectations.

Market effects

Sector

May weigh on other med‑tech stocks facing cybersecurity and competitive pressures.

Regional

Limited to U.S. healthcare sector.

Global

Minimal beyond the med‑tech niche.

Counterpoint

What could challenge this read

Outperform rating remains, suggesting potential upside if the cyber‑incident impact is fully resolved.

Key entities

  • company
    Boston Scientific Corporation

    Medical device maker (ticker BSX).

  • analyst
    Oppenheimer

    Equity research firm issuing the price‑target revision.

Read at source← All news

Related articles

SEP 28
$BSXMedAI 8/10

Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy

The FDA cleared Boston Scientific's SpaceOAR Flex System, a hydrogel spacer for prostate cancer radiotherapy, via the 510(k) pathway. The clearance was based on the HYDROSPACE trial, which evaluates the device's safety and effectiveness in reducing radiation dose to the rectum. The device is intended for patients with low- to intermediate-risk prostate cancer undergoing external beam radiotherapy.

cancernetwork.com2 min
SEP 23
$BSXLow

Boston Scientific Corporation Announces Retirement of Arthur C. Butcher from Executive Vice President and Group President, Medsurg and Asia Pacific, Effective January 1, 2027

Boston Scientific Corporation announced that Arthur C. Butcher will retire as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. He will serve as a senior advisor until February 26, 2027. The company specializes in medical equipment and materials, with significant sales in cardiovascular, endodontic surgery, and neuromodulation products.

marketscreener.com1 min
SEP 23
$BSXLow

Boston Scientific MedSurg, Asia Pacific leader to retire

Boston Scientific (BSX) announced EVP Arthur Butcher will retire at year-end 2026, after 30 years with the company. Butcher, who oversees Asia-Pacific, China, and key business units, will stay as a senior advisor until February 2027. He joined in 1996 and held various leadership roles.

massdevice.com2 min
SEP 21
$BSXMed

BSX Maintained by Oppenheimer -- Price Target Lowered to $65

Oppenheimer maintained its 'Outperform' rating for Boston Scientific (BSX) but lowered its price target from $85 to $65. BSX is trading at $43.17, which is 59.8% undervalued according to its GF Value™ of $107.30. The company has a GF Score™ of 80/100, indicating strong overall performance but lower rankings in momentum and valuation.

gurufocus.com2 min